|
|
|
|
pmid:
|
Ogbourne SM et al. |
Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death. |
2004 |
Cancer Res. |
pmid:15087400
|
Gillespie SK et al. |
Ingenol 3-angelate induces dual modes of cell death and differentially regulates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in melanoma cells. |
2004 |
Mol. Cancer Ther. |
pmid:15634659
|
Hampson P et al. |
PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC. |
2005 |
Blood |
pmid:15845901
|
Cozzi SJ et al. |
Induction of senescence in diterpene ester-treated melanoma cells via protein kinase C-dependent hyperactivation of the mitogen-activated protein kinase pathway. |
2006 |
Cancer Res. |
pmid:17047072
|
Challacombe JM et al. |
Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. |
2006 |
J. Immunol. |
pmid:17114487
|
|
|
|
|
pmid:17115221
|
|
|
|
|
pmid:17264770
|
|
|
|
|
pmid:18265980
|
Serova M et al. |
Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells. |
2008 |
Mol. Cancer Ther. |
pmid:18413805
|
Benhadji KA et al. |
Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells. |
2008 |
Br. J. Cancer |
pmid:19034280
|
|
|
|
|
pmid:19178487
|
|
|
|
|
pmid:19388934
|
Ghoul A et al. |
Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells. |
2009 |
Cancer Res. |
pmid:19417139
|
|
|
|
|
pmid:19428919
|
|
|
|
|
pmid:19467365
|
|
|
|
|
pmid:19922462
|
Li L et al. |
The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature. |
2010 |
Cancer Res. |
pmid:20460505
|
|
|
|
|
pmid:20467815
|
Lee WY et al. |
Novel antileukemic compound ingenol 3-angelate inhibits T cell apoptosis by activating protein kinase Ctheta. |
2010 |
J. Biol. Chem. |
pmid:20472553
|
|
|
|
|
pmid:20546215
|
|
|
|
|
pmid:21325841
|
|
|
|
|
pmid:22055282
|
Cozzi SJ et al. |
Ingenol mebutate field-directed treatment of UVB-damaged skin reduces lesion formation and removes mutant p53 patches. |
2012 |
J. Invest. Dermatol. |
pmid:22189786
|
Fallen RS and Gooderham M |
Ingenol mebutate: an introduction. |
2012 |
Skin Therapy Lett. |
pmid:22358305
|
Lebwohl M et al. |
Ingenol mebutate gel for actinic keratosis. |
2012 |
N. Engl. J. Med. |
pmid:22417254
|
|
|
|
|
pmid:22538622
|
|
|
|
|
pmid:22618984
|
|
|
|
|
pmid:22828167
|
Cozzi SJ et al. |
Effective treatment of squamous cell carcinomas with ingenol mebutate gel in immunologically intact SKH1 mice. |
2013 |
Arch. Dermatol. Res. |
pmid:22871992
|
Doan HQ et al. |
Ingenol mebutate: potential for further development of cancer immunotherapy. |
2012 |
J Drugs Dermatol |
pmid:23134979
|
|
|
|
|
pmid:23134983
|
|
|
|
|
pmid:23228300
|
|
|
|
|
pmid:23228305
|
|
|
|
|
pmid:23231025
|
|
|
|
|
pmid:23302940
|
|
|
|
|
pmid:23362492
|
|
|
|
|
pmid:23550994
|
|
|
|
|
pmid:23553119
|
|
|
|
|
pmid:23673300
|
Song X et al. |
RasGRPs are targets of the anti-cancer agent ingenol-3-angelate. |
2013 |
PLoS ONE |
pmid:23991094
|
Liang X et al. |
Syntheses, biological evaluation and SAR of ingenol mebutate analogues for treatment of actinic keratosis and non-melanoma skin cancer. |
2013 |
Bioorg. Med. Chem. Lett. |
pmid:23993332
|
|
|
|
|
pmid:24005145
|
|
|
|
|
pmid:24048430
|
Edwards SK et al. |
N-benzyladriamycin-14-valerate (AD 198) exhibits potent anti-tumor activity on TRAF3-deficient mouse B lymphoma and human multiple myeloma. |
2013 |
BMC Cancer |
pmid:24131623
|
|
|
|
|
pmid:24509965
|
|
|
|
|
pmid:24595570
|
|
|
|
|
pmid:24742851
|
|
|
|
|
pmid:24918567
|
|
|
|
|
pmid:25016953
|
|
|
|
|
pmid:25052730
|
|
|
|
|
pmid:25070046
|
|
|
|
|
pmid:25115145
|
|
|
|
|
pmid:25186255
|
|
|
|
|
pmid:25217087
|
|
|
|
|
pmid:25268601
|
|
|
|
|
pmid:25409424
|
|
|
|
|
pmid:25545762
|
|
|
|
|
pmid:25561218
|
|
|
|
|
pmid:25607702
|
Cantisani C et al. |
Evaluation of Ingenol mebutate efficacy for the treatment of actinic keratosis with Antera 3D camera. |
2015 |
Eur Rev Med Pharmacol Sci |
pmid:25635981
|
|
|
|
|
pmid:25671445
|
|
|
|
|
pmid:25727104
|
|
|
|
|
pmid:25732962
|
|
|
|
|
pmid:25732966
|
|
|
|
|
pmid:25770879
|
|
|
|
|
pmid:25795391
|
|
|
|
|
pmid:25820019
|
|
|
|
|
pmid:25832754
|
|
|
|
|
pmid:25983016
|
Soini EJ et al. |
Cost-utility of first-line actinic keratosis treatments in Finland. |
2015 |
Adv Ther |
pmid:26006101
|
|
|
|
|
pmid:26055975
|
Stockfleth E et al. |
New Topical Treatment Options for Actinic Keratosis: A Systematic Review. |
2016 |
Acta Derm. Venereol. |
pmid:26068001
|
Freiberger SN et al. |
Ingenol Mebutate Signals via PKC/MEK/ERK in Keratinocytes and Induces Interleukin Decoy Receptors IL1R2 and IL13RA2. |
2015 |
Mol. Cancer Ther. |
pmid:26116359
|
|
|
|
|
pmid:26130156
|
Jiang G et al. |
Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation. |
2015 |
PLoS Pathog. |
pmid:26225771
|
|
|
|
|
pmid:26227007
|
|
|
|
|
pmid:26258811
|
|
|
|
|
pmid:26267725
|
Pellacani G et al. |
A randomized trial comparing simultaneous vs. sequential field treatment of actinic keratosis with ingenol mebutate on two separate areas of the head and body. |
2015 |
J Eur Acad Dermatol Venereol |
pmid:26300464
|
|
|
|
|
pmid:26350885
|
|
|
|
|
pmid:26373693
|
De Felice B et al. |
Ingenol mebutate treatment in keloids. |
2015 |
BMC Res Notes |
pmid:26391582
|
|
|
|
|
pmid:26448312
|
|
|
|
|
pmid:26471889
|
|
|
|
|
pmid:26524598
|
|
|
|
|
pmid:26706239
|
|
|
|
|
pmid:26799440
|
|
|
|
|
pmid:26810403
|
Bhandari PR and Pai VV |
Could ingenol mebutate be useful in managing nonmelanoma skin cancers? |
2015 Apr-Jun |
Indian J Cancer |
pmid:26853424
|
|
|
|
|
pmid:26954321
|
|
|
|
|
pmid:26969886
|
Asche CV et al. |
Evaluation of Resource Utilization and Treatment Patterns in Patients with Actinic Keratosis in the United States. |
2016 Mar-Apr |
Value Health |
pmid:27021759
|
|
|
|
|
pmid:27043050
|
|
|
|
|
pmid:27052110
|
|
|
|
|
pmid:27072602
|
Le TT et al. |
IL-1 Contributes to the Anti-Cancer Efficacy of Ingenol Mebutate. |
2016 |
PLoS ONE |
pmid:27100888
|
|
|
|
|
pmid:27130695
|
|
|
|
|
pmid:27130804
|
|
|
|
|
pmid:27168262
|